401 related articles for article (PubMed ID: 32559715)
1. Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma.
Lin H; Zhang R; Wu W; Lei L
Cancer Genet; 2020 Jul; 245():27-34. PubMed ID: 32559715
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of the Sorafenib-Associated Druggable Targets on Differential Gene Expression and ceRNA Network in Hepatocellular Carcinoma.
Fu Z; Yang G; Wang T; Gao D; Lin D; Liu X
J Environ Pathol Toxicol Oncol; 2023; 42(4):47-60. PubMed ID: 37522567
[TBL] [Abstract][Full Text] [Related]
3. Silencing
Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
[TBL] [Abstract][Full Text] [Related]
4. Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma.
Jiang X; Zhang W; Li L; Xie S
Pathol Oncol Res; 2021; 27():1609985. PubMed ID: 34737677
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of the molecular signature of target genes involved in the antitumor effects of cantharidin on hepatocellular carcinoma.
Yan J; Gao YM; Deng XL; Wang HS; Shi GT
BMC Cancer; 2023 Nov; 23(1):1161. PubMed ID: 38017425
[TBL] [Abstract][Full Text] [Related]
6. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
8. Identification of aberrantly expressed lncRNA and the associated TF-mRNA network in hepatocellular carcinoma.
Wang B; Tang D; Zhang Z; Wang Z
J Cell Biochem; 2020 Feb; 121(2):1491-1503. PubMed ID: 31498488
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.
Yan P; Huang Z; Mou T; Luo Y; Liu Y; Zhou B; Cao Z; Wu Z
BMC Cancer; 2021 Apr; 21(1):436. PubMed ID: 33879119
[TBL] [Abstract][Full Text] [Related]
10. Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma.
Liu J; Qiu WC; Shen XY; Sun GC
Math Biosci Eng; 2019 Jul; 16(6):6319-6334. PubMed ID: 31698564
[TBL] [Abstract][Full Text] [Related]
11. Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines.
Zhang Z; He CZ; Qin YQ; Liao JJ; Huang ST; Mo S; Li HM; Lin JY
Aging (Albany NY); 2020 Nov; 12(23):24255-24269. PubMed ID: 33234725
[TBL] [Abstract][Full Text] [Related]
12. Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma.
Yoo JJ; Yu SJ; Na J; Kim K; Cho YY; Lee YB; Cho EJ; Lee JH; Kim YJ; Youn H; Yoon JH
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875800
[TBL] [Abstract][Full Text] [Related]
13. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
14. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
[TBL] [Abstract][Full Text] [Related]
15. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
[TBL] [Abstract][Full Text] [Related]
16. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis.
Zhou Z; Li Y; Hao H; Wang Y; Zhou Z; Wang Z; Chu X
Cell Transplant; 2019 Dec; 28(1_suppl):76S-86S. PubMed ID: 31822116
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential miRNA-mRNA regulatory network contributing to pathogenesis of HBV-related HCC.
Lou W; Liu J; Ding B; Chen D; Xu L; Ding J; Jiang D; Zhou L; Zheng S; Fan W
J Transl Med; 2019 Jan; 17(1):7. PubMed ID: 30602391
[TBL] [Abstract][Full Text] [Related]
18. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis.
Shen S; Kong J; Qiu Y; Yang X; Wang W; Yan L
J Cell Biochem; 2019 Jun; 120(6):10069-10081. PubMed ID: 30525236
[TBL] [Abstract][Full Text] [Related]
19. The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating
Wang S; Liu D; Wei H; Hua Y; Shi G; Qiao J
Bioengineered; 2022 Feb; 13(2):2272-2284. PubMed ID: 35034536
[TBL] [Abstract][Full Text] [Related]
20. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
